Life Technologies Remains Neutral - Analyst Blog
February 23 2012 - 10:15AM
Zacks
We reaffirm our Neutral
recommendation on Life Technologies (LIFE)
following its fourth-quarter 2011 results. The company
reported a strong quarter with both revenues and adjusted EPS going
past the Zacks Consensus Estimates.
Life Technologies’ performance has
been adversely affected by a sustained slowdown in government and
academic research funding over the past few quarters, a trend that
is expected to continue in 2012. This is significant since the
company derives almost 45% of its revenues from these
customers.
However, the company is
repositioning itself for a slower growth environment by lowering
its cost structure and increasing its focus on R&D initiatives.
The company has recorded robust revenue (CAGR of 12% to $3.73
billion in 2011) and earnings growth (23% to $3.73 per share) over
the past 3 years. Moreover, free cash flow clocked 33% growth over
the same period.
Over the past couple of years, the
company has been focusing on creating an optimal portfolio of
products through innovations and acquisitions, the latest being Ion
Torrent. The company derives 20% of revenues from proprietary
instruments, which in turn drive demand for the high-margin
consumables that account for the remaining 80%.
We are also encouraged by Life’s
strategy to strengthen its presence in high growth geographic
markets such as Latin America, the Middle-East, China and India.
Life Technologies sniffs immense potential in applied markets where
technologies can facilitate biological research in fast growing
industries such as forensics, food and water testing. Over the next
few years, Life’s focus on developing industry-leading franchises
in high-growth technology areas, applied markets and emerging
geographies will be the key drivers for long-term growth.
We are impressed with the robust
growth recorded by the Ion Personal Genome Machine (“PGM”) that was
launched in December 2010 taking the total number of system
placements to 700 in 2011. Maintaining the upbeat trend, PGM sales
were strong during the reported quarter, growing on a sequential
basis.
The company is satisfied with the
progress made so far with Ion Torrent technologies and expects the
growth momentum to continue. This growth will be supported by more
PGM placements and the scheduled launch of Ion Proton Benchtop
sequencer in the second half. In October 2011, the Ion franchise
was further boosted by the launch of the Ion AmpliSeq Cancer Panel
to help scientists to sequence dozens of genes in cancer research
samples using a simple workflow. With the launch of new products,
contribution of the Ion portfolio is expected to increase over the
next few quarters.
Life Technologies sets much in
store by the scheduled launch of the Ion Proton sequencer in the
second half of 2012 though competition in the DNA sequencing market
is increasing. While Illumina (ILMN) plans to
launch its HiSeq 2500 in the second half, Oxford Nanopore
Technologies’ MinION is also in the queue, which is a disposable
DNA sequencing device the size of a USB memory stick.
Our recommendation is backed by a
Zacks #3 Rank (“Hold”) in the short term.
ILLUMINA INC (ILMN): Free Stock Analysis Report
LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From May 2024 to Jun 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Jun 2023 to Jun 2024